Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses

SIMPLE SUMMARY: How tumor response and progression-free survival (PFS) reflect the overall survival (OS) in advanced non-small cell lung cancer (NSCLC) clinical trials with immune checkpoint inhibitors (ICI) have not been clarified. This study validated the uses of objective response rate and PFS fo...

Descripción completa

Detalles Bibliográficos
Autor principal: Horita, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818635/
https://www.ncbi.nlm.nih.gov/pubmed/36612179
http://dx.doi.org/10.3390/cancers15010185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818635/
https://www.ncbi.nlm.nih.gov/pubmed/36612179
http://dx.doi.org/10.3390/cancers15010185

Ejemplares similares